ImageneBio, Inc.
IMA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001835579
In the last 90 days, ImageneBio, Inc. insiders filed 0 open-market purchases and 1 sale; 35 institutions reported holding it in 13F filings for Q2 2026, worth $36.8M in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding ImageneBio, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 34 | 39 | +5 |
| Shares | 26.3M | 25.0M | −1.28M (−4.9%) |
| Value | $69.9M | $86.2M | +$16.3M (+23.4%) |
New holders (7)
Institutions that held ImageneBio, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 39,732 | $137.1K | 0.00% |
| Jane Street Group, LLC | 38,318 | $132.2K | 0.00% |
| Goldman Sachs Group Inc | 35,192 | $121.4K | 0.00% |
| Jacobs Levy Equity Management, Inc | 18,144 | $62.6K | 0.00% |
| UBS Group AG | 624 | $2.15K | 0.00% |
| Royal Bank of Canada | 265 | $1.00K | 0.00% |
| US Bancorp | 218 | $752 | 0.00% |
Sold out (2)
Institutions that held ImageneBio, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Oasis Management Co Ltd. | 140,000 | $372.4K |
| Ergoteles LLC | 17,606 | $46.8K |